Wegrzyn leaves ARPA-H after Trump transition

Renee Wegrzyn spent her career building American science, including as inaugural director of ARPA-H, the White House agency created to accelerate health breakthroughs. The Trump administration brought her tenure to an end.

Wegrzyn was a presidential appointee with term limits

Wegrzyn held an unusual appointment as a presidential appointee who was term-limited. She served through the transition and had a few weeks in the new administration. She also served in Trump one.

She convinced them ARPA-H was worth keeping

Wegrzyn showed the new administration what ARPA-H was building and convinced them the agency was worth keeping around. She remains proud of the agency and its perseverance despite her departure.

ARPA-H filled a gap in how science was done

ARPA-H was needed because something was missing in the way science was being done broadly. The agency focused on moving quickly and getting focused on a problem versus building a general knowledge set.

Wegrzyn is still amped up about the possibilities

Despite leaving ARPA-H, Wegrzyn remains enthusiastic about its mission. She notes that DARPA has been around for almost eighty years and hopes ARPA-H will have the same longevity and continue to live on today.

“I'm still amped up about it. It's still an amazing idea.”

Leaving was hard but she's a builder

Wegrzyn describes herself as a builder who loves to take things forward and show what's possible.

“I'm a builder. I love to take things forward and really show what's possible.”

Wegrzyn cofounded Transfyr after leaving

After leaving ARPA-H, Wegrzyn cofounded Transfyr to tackle what she calls one of the most overlooked issues in science: the magic hands problem.

The magic hands problem is unglamorous

Wegrzyn explains that fixing the magic hands problem is an unglamorous bottleneck in science. She argues that solving this issue is the prerequisite for everything AI promises to deliver in medicine.

She senses a Sputnik moment coming

Wegrzyn says she can feel the next Sputnik moment coming, even if she cannot quite name it yet. She expresses concern that America may be losing its scientific edge in the current landscape.

Transfyr aims to bridge lab and real world

Transfyr uses artificial intelligence to help medical breakthroughs move from the laboratory into real-world application. Wegrzyn believes this bridge is essential for unlocking the full potential of AI in medicine.